Condition
Merkel Cell Carcinoma, Stage IV
Total Trials
1
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
Treatment Research
1 treatments under study, led by Astx727 Retifanlimab
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 1/2 (1)
Trial Status
Not Yet Recruiting1
Clinical Trials (1)
Showing 1 of 1 trials
Showing all 1 trials
Research Network
Common Treatments
- Astx727 Retifanlimab1
Active Sponsors
- University of Wisconsin, Madison1
Top Investigators
University of Wisconsin, Madison
Related Conditions
- Merkel Cell Carcinoma Stage Iii1
- Merkel Cell Carcinoma1